Traditionally, hemophilia treatment has leveraged injections of a clotting factor or plasma. Learn more about how stem cells may hold promise for treating hemophilia using a cellular approach.
In this article:
Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions
MONT-SAINT-GUIBERT, Belgium — Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its first-of-its kind facility dedicated to manufacturing therapies based on induced pluripotent stem cells (iPSCs). This achievement signifies Cellistic’s quality and regulatory readiness, which is now certified by the Belgian Federal Agency for Medicines and Health Products (FAMHP), operating under European Medicines Agency (EMA) guidelines. [Read more…]
Autolus Latest Competitor in Global CAR-T Frenzy with FDA Approval of Aucatzyl
On November 8, 2024, the U.S. FDA issued a historic approval of the seventh CAR-T cell therapy to be approved in the U.S. and the 11th CAR-T therapy to be approved globally. This approval was for Autolus Inc.’s Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Autolus is a U.K. biotech company that develops novel gene-modified T cell therapies for the treatment of cancer. [Read more…]
9 Reasons Cell Therapy is the Future of Human Health
Cell therapy is the use of cells and tissues to regenerate, repair, and in some instances, even enhance human health. Traditionally, the modern medical system has relied on a pharmaceutical-based approach. This led to the rise of the U.S. Food and Drug Administration (FDA) which was founded in 1906, making it 111 years old this year. Unfortunately, our approach to human health has not experienced a dramatic shift over the past 100+ years, and as a society, we still tend to rely on a drug-based approach.
Below, we profile eight strengths of cell therapy that will propel cell therapies to the forefront of mainstream medicine.
In this article:
CDMO Avid Bioservices to Go Private in $1.1 Billion Acquisition
A dominant cell and gene therapy (CGT) CDMO, Avid Bioservices, Inc. (NASDAQ: CDMO) has announced it will be going private in a hefty $1.1 billion acquisition by GHO Capital Partners and Ampersand Capital Partners. The deal, an all-cash transaction, is set to shift Avid from a publicly traded company to a lucratively funded and strategically agile private entity. [Read more…]
- « Previous Page
- 1
- …
- 88
- 89
- 90
- 91
- 92
- …
- 339
- Next Page »